Snapshot from Aug 16, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Proteotype Unveils Alchemi Platform
Tech Product Launch

Proteotype Unveils Alchemi Platform

Analysis based on 7 articles · First reported Jul 30, 2026 · Last updated Jul 30, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The unveiling of Alchemi signals Proteotype's progress in building the digital infrastructure for its multi-cancer test, potentially enhancing its attractiveness to investors and partners. The EIC grant provides non-dilutive funding, supporting development without immediate equity dilution, which may positively influence the company's valuation in future funding rounds.

Biotechnology Healthcare Medical Devices
Event Summary

Proteotype Diagnostics, a Portuguese diagnostics company, unveiled Alchemi, its proprietary data and clinical workflow platform designed to support its investigational blood-based multi-cancer test, Enlighten. Alchemi aims to standardize laboratory measurements, govern machine-learning workflows, and generate traceable clinician-facing outputs, with interoperability standards such as HL7 FHIR and SNOMED CT. The platform is intended to enable secure, multi-country data harmonization and reduce reliance on a single central testing facility. Development is supported by approximately €499,000 from the European Council's Pre-Accelerator program, with a 15-month program starting September 1, 2026. Proteotype was among 70 deep-tech companies selected from 22 countries under the EIC call, which awarded about €32.5 million in total funding. The company is recruiting for software engineering, data engineering, cybersecurity, and healthcare integration roles at its Torres Vedras site.

Key Actions
100 Proteotype Diagnostics unveiled
90 European Council awarded grant Proteotype Diagnostics
Entities Involved
priv
Proteotype Diagnostics
Proteotype is the developer of Alchemi and Enlighten, and this announcement highlights its technological advancement and grant support, potentially boosting its credibility and funding prospects.
Importance 100.0 Sentiment 60.0
alliance
European Council
The EIC provided a €499,000 grant to Proteotype, part of its Pre-Accelerator program, reinforcing its role in supporting deep-tech innovation across Europe.
Importance 70.0 Sentiment 20.0
per
Wesley Sukdao
As CEO and co-founder, Sukdao is a key spokesperson for the company, and his statements underscore the strategic importance of Alchemi.
Importance 40.0 Sentiment 20.0
per
Emma Yates
As Chief Scientific Officer, Yates emphasizes the scientific rigor and traceability of the platform, reinforcing the company's technical credibility.
Importance 40.0 Sentiment 20.0
per
Goncalo Bernardes
As co-founder and chair of the scientific advisory board, Bernardes lends academic prestige and supports the integration of biology and technology.
Importance 30.0 Sentiment 20.0
loc
Portugal
Portugal is the home country of Proteotype, and the development is led from Torres Vedras, potentially contributing to the local biotech ecosystem.
Importance 30.0 Sentiment 20.0
alliance
European Union
The EU, through the EIC, funds the project, reflecting its commitment to fostering innovation and competitiveness in the European deep-tech sector.
Importance 30.0 Sentiment 20.0
Relationships
European Council related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.